Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00238628
Status:
COMPLETED
Last Update Posted:
2010-07-20
First Post:
2005-10-11
Brief Title:
A Phase III Study of Bexarotene in Combination With ZD1839 IRESSA in the Treatment of Non-Small Cell Lung Cancer
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
A Phase III Study of Bexarotene in Combination With ZD 1839 IRESSA in the Third Line Treatment of Non-Small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen bexarotene and ZD1839 Phase II will evaluate the median survival time to disease progression and toxicity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCT00238628 | None | None | None |
| 80031 | None | None | None |
| IRUSIRES0436 | None | None | None |
| LUN0005 | None | None | None |